What is a stock summary page? Click here for an overview.
Business Description
Lyell Immunopharma Inc
NAICS : 325412
SIC : 2834
ISIN : US55083R1041
Share Class Description:
LYEL: Ordinary SharesDescription
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 6.5 | |||||
| Equity-to-Asset | 0.78 | |||||
| Debt-to-Equity | 0.15 | |||||
| Debt-to-EBITDA | -0.29 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 1/9 | |||||
| Altman Z-Score | -4.4 | |||||
| Beneish M-Score | -3.37 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 17.1 | |||||
| 3-Year EPS without NRI Growth Rate | 22.5 | |||||
| 3-Year FCF Growth Rate | 23.9 | |||||
| 3-Year Book Growth Rate | -30.3 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 4.33 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 44.7 | |||||
| 9-Day RSI | 43.14 | |||||
| 14-Day RSI | 43.78 | |||||
| 3-1 Month Momentum % | 8.52 | |||||
| 6-1 Month Momentum % | -54.45 | |||||
| 12-1 Month Momentum % | -65.36 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 7.06 | |||||
| Quick Ratio | 7.06 | |||||
| Cash Ratio | 7.13 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -6.7 | |||||
| Shareholder Yield % | 3.64 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -361104.92 | |||||
| Net Margin % | -562285.25 | |||||
| FCF Margin % | -266980.33 | |||||
| ROE % | -62.63 | |||||
| ROA % | -53.45 | |||||
| ROIC % | -129.68 | |||||
| 3-Year ROIIC % | 1.4 | |||||
| ROC (Joel Greenblatt) % | -189.06 | |||||
| ROCE % | -36.43 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 0.42 | |||||
| Price-to-Tangible-Book | 0.42 | |||||
| EV-to-EBIT | 0.67 | |||||
| EV-to-EBITDA | 0.71 | |||||
| EV-to-Revenue | -2410.3 | |||||
| EV-to-Forward-Revenue | 2714.91 | |||||
| EV-to-FCF | 0.95 | |||||
| Price-to-GF-Value | 0.14 | |||||
| Price-to-Net-Current-Asset-Value | 0.59 | |||||
| Price-to-Net-Cash | 0.59 | |||||
| Earnings Yield (Greenblatt) % | 149.25 | |||||
| FCF Yield % | -101.74 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:LYEL
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Lyell Immunopharma Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0.061 | ||
| EPS (TTM) ($) | -1.241 | ||
| Beta | -0.56 | ||
| 3-Year Sharpe Ratio | -0.46 | ||
| 3-Year Sortino Ratio | -0.66 | ||
| Volatility % | 76.96 | ||
| 14-Day RSI | 43.78 | ||
| 14-Day ATR ($) | 0.069354 | ||
| 20-Day SMA ($) | 0.639 | ||
| 12-1 Month Momentum % | -65.36 | ||
| 52-Week Range ($) | 0.481 - 3.145 | ||
| Shares Outstanding (Mil) | 295.23 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Lyell Immunopharma Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Lyell Immunopharma Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Lyell Immunopharma Inc Frequently Asked Questions
What is Lyell Immunopharma Inc(LYEL)'s stock price today?
The current price of LYEL is $0.54. The 52 week high of LYEL is $3.15 and 52 week low is $0.48.
When is next earnings date of Lyell Immunopharma Inc(LYEL)?
The next earnings date of Lyell Immunopharma Inc(LYEL) is 2025-05-06 Est..
Does Lyell Immunopharma Inc(LYEL) pay dividends? If so, how much?
Lyell Immunopharma Inc(LYEL) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers